Obstetrics, gynecology, andrology, sexual and reproductive health

Breast diseases

PubMed Free Full Text

Breast cancer treatment

 

Arab countries

• Health and Quality of Life Outcomes
  • Quality of life in Arab women with breast cancer: a review of the literature [2016]

Asia

• BMJ Open
  • Health-related quality of life in Asian patients with breast cancer: a systematic review [2018]

• Journal of Breast Cancer
  • Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide [2016]

• PLoS ONE
  • Predicting Survival of De Novo Metastatic Breast Cancer in Asian Women: Systematic Review and Validation Study [2014]

Australia

• Australian Journal of General Practice
  • Update on the management of early-stage breast cancer [2019]
  • Advanced breast cancer [2019]

• Cancer Australia
  • Guidance for the management of early breast cancer: Recommendations and practice points [2020]
  • Guidance for the management of early breast cancer: Methods [2020]
  • Recommendations for follow-up of women with early breast cancer [2010]

• Journal of Comorbidity
  • Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study [2018]

• PLoS ONE
  • Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice [2014]

Austria

• SpringerPlus
  • Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria [2015]

Brazil

• International Journal of Environmental Research and Public Health
  • Waiting Time between Breast Cancer Diagnosis and Treatment in Brazilian Women: An Analysis of Cases from 1998 to 2012 [2020]

Canada

• Breast Cancer Research and Treatment
  • A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles [2022]

• Canadian Agency for Drugs and Technologies in Health
  • Regional Chemotherapy for the Treatment of Breast Cancer: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines [2018]

• Canadian Family Physician
  • Breast Cancer Survivorship Tool [2020]
  • Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians [2016]

• Current Oncology
  • Systemic treatment approaches in her2-negative advanced breast cancer—guidance on the guidelines [2015]
  • Optimal systemic therapy for early breast cancer in women: a clinical practice guideline [2015]
  • Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada [2013]

• Ontario Health
  • Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Cancer Care Ontario’s Position Statement on Guidelines for Breast Cancer Well Follow-Up Care [2012]

Canada, United States

• CA: A Cancer Journal for Clinicians
  • Clinical practice guidelines on the evidence-based use of integrative therapies during and following breast cancer treatment [2017]

China

• Annals of Translational Medicine
  • Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study [2021]

• Chinese Medical Journal
  • Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021 [2021]

• Frontiers in Oncology
  • Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China [2021]

• Journal of Oncology
  • Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China [2021]

• Oncotarget
  • A nation-wide multicenter 10-year (1999–2008) retrospective study of chemotherapy in Chinese breast cancer patients [2017]

Europe

• BMC Cancer
  • Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe [2015]

• BMC Health Services Research
  • Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries [2020]

• Clinical Breast Cancer
  • A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer [2017]

• European Society for Medical Oncology
  • Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies [2020]

Europe, United States

• Cancers
  • FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis [2020]

Germany

• BMC Cancer
  • The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients [2015]

• Breast Cancer
  • Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study [2018]

• Breast Care
  • International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts [2020]
  • Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019) [2019]
  • ABC4 Consensus: Assessment by a German Group of Experts [2018]
  • ABC3 Consensus: Assessment by a German Group of Experts [2016]
  • 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus – Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts [2015]
  • Guideline Conformity Treatment in Young Women with Early-Onset Breast Cancer in Germany [2014]
  • 13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus – Opinion of a German Team of Experts (Zurich 2013) [2013]

• Geburtshilfe und Frauenheilkunde
  • Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference [2021]
  • AGO Algorithms for the Treatment of Breast Cancer: Update 2021 [2021]
  • ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results [2020]
  • Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer [2018]
  • 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts [2018]
  • Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus [2017]
  • ABC3 Consensus Commented from the Perspective of the German Guidelines [2016]
  • Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015) [2015]

• Institute for Quality and Efficiency in Health Care
  • Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V [2017]

• International Journal of Cancer
  • Time trends of neoadjuvant chemotherapy for early breast cancer [2020]

Greece

• BMC Health Services Research
  • Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study [2015]

India

• Indian Journal of Medical Research
  • Consensus on contentious issues relevant for breast cancer management for the Indian scenario: Statements following a multicentre expert group meeting [2021]
  • Breast cancer survivorship in India [2021]

• Indian Journal of Surgery
  • Indian Solutions for Indian Problems—Association of Breast Surgeons of India (ABSI) Practical Consensus Statement, Recommendations, and Guidelines for the Treatment of Breast Cancer in India [2017]

• Journal of Cancer Research and Therapeutics
  • Patient-reported quality of life outcomes in Indian breast cancer patients: Importance, review of the researches, determinants and future directions [2013]

• South Asian Journal of Cancer
  • Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India [2021]

International

• Annals of Oncology
  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [2015]

• BMJ Open
  • Evidence-based recommendations on care for breast cancer survivors for primary care providers: a review of evidence-based breast cancer guidelines [2017]

• Breast
  • Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review [2020]

• Breast Care
  • St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer [2021]
  • St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [2019]

• Breast Health Global Initiative
  • Breast cancer treatment: A phased approach to implementation [2020]

• Cancer Treatment Reviews
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge [2021]

• European Society for Medical Oncology
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [2020]
  • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [2018]
  • 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) [2017]

• Geburtshilfe und Frauenheilkunde
  • Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel [2021]

• Health Expectations
  • Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review [2020]

• JCO Global Oncology
  • Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact [2021]

• Journal of Cancer Survivorship
  • Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines [2021]

• Journal of the National Cancer Institute
  • International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? [2010]
  • International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy [2009]

• NPJ Breast Cancer
  • Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic [2020]

• Oncotarget
  • Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer [2018]

• PLoS ONE
  • Global treatment costs of breast cancer by stage: A systematic review [2018]

Ireland, Netherlands

• PLoS ONE
  • Treatment Strategies and Survival of Older Breast Cancer Patients – An International Comparison between the Netherlands and Ireland [2015]

Italy

• BMC Cancer
  • An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project [2018]

• Breast
  • Influence of adherence with guideline-driven recommendations on survival in women operated for breast cancer: Real-life evidence from Italy [2020]

Japan

• Breast Cancer
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition [2020]
  • Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer [2013]

• Japanese Journal of Clinical Oncology
  • The Transition of Breast Cancer Treatment and Japan Clinical Oncology Group Research Over Two Decades [2012]

Latin America and the Caribbean

• Oncologist
  • Health-Related Quality of Life in Patients with Breast Cancer in Latin America and the Caribbean: A Systematic Review and Meta-Analysis [2021]

Low and middle income countries

• BMC Cancer
  • Essential medicines for breast cancer in low and middle income countries [2015]

• Breast Health Global Initiative
  • Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement [2013]
  • Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement [2013]

Morocco

• Breast Journal
  • Management of breast cancer during COVID-19 pandemic in Morocco [2020]

Netherlands

• BMC Cancer
  • Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands [2016]

• Breast Cancer Research and Treatment
  • The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients [2021]
  • The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands [2021]

New Zealand

• Breast
  • New Zealand experience with implementation of the ESO-ESMO consensus guidelines for advanced breast cancer-report of achievements and lessons learned [2022]

• International Journal of Environmental Research and Public Health
  • Use of Non-Cancer Medications in New Zealand Women at the Diagnosis of Primary Invasive Breast Cancer: Prevalence, Associated Factors and Effects on Survival [2020]

Nigeria

• ecancermedicalscience
  • Assessment of guideline adherence in breast cancer management among oncologists in Nigeria [2021]

Norway

• Breast Cancer Research and Treatment
  • Stage-specific survival has improved for young breast cancer patients since 2000: but not equally [2020]

Republic of Korea

• Annals of Surgical Treatment and Research
  • The reality in the follow-up of breast cancer survivors: survey of Korean Breast Cancer Society [2015]

• ClinicoEconomics and Outcomes Research
  • Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea [2016]

• Journal of Breast Cancer
  • Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013 [2015]
  • Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference [2014]

• Journal of Korean Medical Science
  • Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data [2018]

• Nutrients
  • Adherence to Guidelines for Cancer Survivors and Health-Related Quality of Life among Korean Breast Cancer Survivors [2015]

Serbia

• JBUON
  • Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE [2018]

Singapore

• Scientific Reports
  • Impact of deviation from guideline recommended treatment on breast cancer survival in Asia [2020]

Spain

• Clinical and Translational Oncology
  • Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC) [2018]
  • Defining the optimal sequence for the systemic treatment of metastatic breast cancer [2016]

• Health and Quality of Life Outcomes
  • Health-related quality of life in Spanish breast cancer patients: a systematic review [2011]

• Journal of Drug Assessment
  • Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists [2019]

• Oncologist
  • GEICAM Guidelines for the Management of Patients with Breast Cancer During Spain's COVID-19 Pandemic [2020]

• Scientific Reports
  • Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study [2021]

• Sociedad Española de Oncología Médica
  • SEOM clinical guidelines in early stage breast cancer (2018) [2019]
  • SEOM clinical guidelines in advanced and recurrent breast cancer (2018) [2019]
  • Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC) [2018]
  • SEOM clinical guidelines in metastatic breast cancer 2015 [2015]

Sub-Saharan Africa

• Breast Cancer Research
  • Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study [2019]

Switzerland

• Cancers
  • Management and Outcome of Young Women (=40 Years) with Breast Cancer in Switzerland [2022]

Taiwan

• Breast
  • Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan [2021]

• Scientific Reports
  • Health Services Utilisation in Breast Cancer Survivors in Taiwan [2014]

Turkey

• Turkish Journal of Surgery
  • Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak [2020]

United Kingdom

• Association of Breast Surgery
  • Endocrine Treatment for Breast Cancer [2021]

• BMJ Open
  • Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer [2021]

• British Journal of Cancer
  • Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study [2021]

• Cancer Biology & Medicine
  • The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UK [2015]

• Healthcare Improvement Scotland
  • External assurance of performance against Breast Cancer QPIs - National review report: December 2016 [2016]
  • Breast Cancer Clinical Quality Performance Indicators [2016]

• Indian Journal of Surgery
  • Breast Cancer Management Guidelines During COVID-19 Pandemic [2020]

• National Institute for Health and Care Excellence
  • Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy [2023]
  • Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [2022]
  • Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2022]
  • Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer [2022]
  • Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence [2022]
  • Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2021]
  • Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2021]
  • Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2019]
  • Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen [2018]
  • Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2017]
  • Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2017]
  • Everolimus with exemestane for treating advanced breast cancer after endocrine therapy [2016]
  • Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens [2016]
  • Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 [2012]
  • Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer [2006]

United States

• American Cancer Society
  • American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline [2015]

• American College of Radiology
  • Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer
  • Locally Advanced Breast Cancer

• American Society of Breast Surgeons
  • Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries [2021]

• American Society of Clinical Oncology
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline [2021]
  • Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update [2021]
  • Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update [2021]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update [2020]
  • Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline [2019]
  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update [2018]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update [2018]
  • Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline [2018]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update [2017]
  • Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline [2016]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [2016]
  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update [2013]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
  • Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
  • Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
  • Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative

• ASCO Educational Book
  • What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care [2020]

• Breast Cancer : Basic and Clinical Research
  • Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database [2020]

• Breast Cancer : Targets and Therapy
  • Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis [2021]

• Breast Cancer Research and Treatment
  • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium [2020]
  • Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG) [2018]
  • Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) [2018]
  • Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines [2013]

• Cancer Medicine
  • Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey [2015]

• Cancers
  • Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer [2022]

• Chinese Clinical Oncology
  • Chemotherapy principles of managing stage IV breast cancer in the United States [2016]

• Current Breast Cancer Reports
  • Lessons Learned: Management of Breast Cancer Patients throughout the COVID-19 Pandemic [2021]

• Food and Drug Administration
  • FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer [2015]

• JAMA Network Open
  • Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer [2020]

• JAMA Oncology
  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States [2017]

• JCO Oncology Practice
  • Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach [2020]

• Journal of Cancer
  • Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer [2014]

• Journal of Oncology Practice
  • Improved Breast Cancer Care Quality Metrics After Implementation of a Standardized Tumor Board Documentation Template [2015]

• National Cancer Institute
  • Childhood Breast Cancer Treatment (PDQ®)
  • Breast Cancer Treatment (PDQ®)

• National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 [2021]
  • NCCN resource-stratified and harmonized guidelines: A paradigm for optimizing global cancer care [2020]

• Society for Immunotherapy of Cancer
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer [2021]

• Society for Integrative Oncology
  • Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment [2017]

{Related topics}

• Guidelines
  • Breast cancer treatment: vinca alkaloids
  • Breast cancer treatment: tyrosine kinase inhibitors
  • Breast cancer treatment: taxanes
  • Breast cancer treatment: surgery, radiotherapy
  • Breast cancer treatment: monoclonal antibodies
  • Breast cancer treatment: epothilones
  • Breast cancer treatment: bisphosphonates
  • Breast cancer treatment: aromatase inhibitors
  • Breast cancer treatment: antimetabolites
  • Breast cancer treatment: antiestrogens
  • Breast cancer treatment: anthracyclines
  • Breast cancer